<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02526732</url>
  </required_header>
  <id_info>
    <org_study_id>2015_04_001_HELP</org_study_id>
    <nct_id>NCT02526732</nct_id>
  </id_info>
  <brief_title>Hepatic Inflammation and Physical Performance in Patients With NASH</brief_title>
  <acronym>HELP</acronym>
  <official_title>Influence of Hepatic Inflammation and Hepatocellular Apoptosis on Physical Performance and Training Effect in Patients With Non - Alcoholic Steatohepatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Priv.-Doz. Dr. J. Schattenberg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johannes Gutenberg University Mainz</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to examine the influence of hepatic inflammation or damage on
      physical performance (maximal oxygen uptake, VO2max) depending on the histologic state of the
      liver. The study population are patients with fatty liver disease and non-alcoholic
      steatohepatitis (NASH). All study participants obtain an individual training plan with
      individual and group training sessions for a period of 8 weeks. At the beginning and end of
      the training phase a sport physiological examination is carried out. In the study group the
      effect of regular examinations is surveyed by surrogate parameters of liver inflammation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is planned over a period of 24 months. Study participants should be twice examined
      sport physiologically in a period of 12 weeks. In the study group the influence of regular
      exercise on surrogate parameters of liver inflammation is investigated over a study period of
      8 weeks. Before the exercise all study participants are subjected to a first physiological
      examination (about 3 hours). This includes a physical examination with detection of body
      weight, waist circumference and body fat analysis, venous blood, oral glucose tolerance test,
      ultrasonography of the liver and determination of endothelial function (flow-mediated
      vasodilatation, FMD) by Doppler analysis. Within 4 weeks after the first examination a sport
      physical examination is carried out at the Institute of Sports Science at the University of
      Mainz. This examination contains identification of physical fitness and individual lactate
      performance diagnostics. In addition, indirect calorimetry is carried out under exercise
      conditions using spiroergometry to determine the maximal oxygen uptake (VO2max) with special
      emphasis on the fat metabolism rate at low physical activity. Subsequently to the examination
      an 8-week training period based on individual training / performance plans is followed. The
      training plans include independently running exercises for 30-45 minutes two to three times a
      week. Every two weeks group training sessions are offered accompanied by a sports physician.
      Within the planed four groups training sessions blood samples will be taken to determinate
      free circulating DNA and assess lactate values under exercise conditions. After the training
      phase, a second sport physical examination including physical performance and a final
      physiological examination including surrogate parameters of liver inflammation are carried
      out. For statistical analysis, the physical performance of the study participants is
      examined. Hence patients with histologically proven NASH (NAS score) and confirmed
      inflammation (increased M30 antigen) are compared to age and gender matched patients with
      histologically proven fatty liver without inflammation reaction as well as to retrospective
      data of healthy subjects.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">September 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in physical performance</measure>
    <time_frame>0-8 weeks</time_frame>
    <description>Change of Vo2max from week 0 to week 8</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in liver inflammation</measure>
    <time_frame>8 weeks</time_frame>
    <description>Change of NAS score at week 0 and week 8</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Non-alcoholic Fatty Liver Disease</condition>
  <arm_group>
    <arm_group_label>individual training program</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be offered an individual training program. Physical performance and surrogate parameters of liver inflammation will assessed in physical examinations before and after the training phase.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>individual training program</intervention_name>
    <description>Training period of 8 weeks: Independently running exercises for 30-45 minutes two to three times a week. Every two weeks group training sessions are offered accompanied by a sports physician.</description>
    <arm_group_label>individual training program</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  histologically proven NASH or fatty liver disease

        Exclusion Criteria:

          -  bariatric surgery within the last 5 years

          -  BMI&lt; 18,5 kg/m2 or &gt; 45 kg/m2

          -  heart attack or stroke within the last 6 months

          -  higher-grade coronary artery disease (CAD III-IV)

          -  chronic obstructive pulmonary disease (asthma , COPD)

          -  renal insufficiency

          -  uncontrolled hypertension or metabolic abnormalities

          -  alcohol consumption &gt; 30 g / day (male) and &gt; 20 g / day (female)

          -  pregnancy

          -  concomitant medication able to cause a secondary NASH (eg tamoxifen , corticosteroids
             )

          -  concomitant medication able to affect inflammation (eg TNF antagonists)

          -  concomitant anticoagulant medication (eg phenprocoumon, NOAC)

          -  other immunological or inflammatory diseases (eg, systemic lupus erythematosus)

          -  musculoskeletal disorders, preventing sport physiological investigations
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter R Galle, MD</last_name>
    <role>Study Director</role>
    <affiliation>I. Medizinische Klinik und Poliklinik, Universitätsmedizin Mainz</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jörn M Schattenberg, MD</last_name>
    <phone>+49 (0)6131 17</phone>
    <phone_ext>6074</phone_ext>
    <email>joern.schattenberg@unimedizin-mainz.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yvonne Alt, MD</last_name>
    <email>yvonne.alt@unimedizin-mainz.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Medical Center of the Johannes Gutenber Univeristy</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jörn M Schattenberg, MD</last_name>
      <phone>+496131176074</phone>
      <email>joern.schattenberg@unimedizin-mainz.de</email>
    </contact>
    <contact_backup>
      <last_name>Yvonne Alt, MD</last_name>
      <email>yvonne.alt@unimedizin-mainz.de</email>
    </contact_backup>
    <investigator>
      <last_name>Jörn M Schattenberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Perikles Simon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yvonne Alt, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jens Kittner, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Clark JM. The epidemiology of nonalcoholic fatty liver disease in adults. J Clin Gastroenterol. 2006 Mar;40 Suppl 1:S5-10. Review.</citation>
    <PMID>16540768</PMID>
  </reference>
  <reference>
    <citation>Blachier M, Leleu H, Peck-Radosavljevic M, Valla DC, Roudot-Thoraval F. The burden of liver disease in Europe: a review of available epidemiological data. J Hepatol. 2013 Mar;58(3):593-608. doi: 10.1016/j.jhep.2012.12.005. Review.</citation>
    <PMID>23419824</PMID>
  </reference>
  <reference>
    <citation>Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011 Aug;34(3):274-85. doi: 10.1111/j.1365-2036.2011.04724.x. Epub 2011 May 30. Review.</citation>
    <PMID>21623852</PMID>
  </reference>
  <reference>
    <citation>Sanyal AJ. NASH: A global health problem. Hepatol Res. 2011 Jul;41(7):670-4. doi: 10.1111/j.1872-034X.2011.00824.x.</citation>
    <PMID>21711426</PMID>
  </reference>
  <reference>
    <citation>Mehal WZ. The Gordian Knot of dysbiosis, obesity and NAFLD. Nat Rev Gastroenterol Hepatol. 2013 Nov;10(11):637-44. doi: 10.1038/nrgastro.2013.146. Epub 2013 Aug 20. Review.</citation>
    <PMID>23958600</PMID>
  </reference>
  <reference>
    <citation>Schattenberg JM, Schuppan D. Nonalcoholic steatohepatitis: the therapeutic challenge of a global epidemic. Curr Opin Lipidol. 2011 Dec;22(6):479-88. doi: 10.1097/MOL.0b013e32834c7cfc. Review.</citation>
    <PMID>22002020</PMID>
  </reference>
  <reference>
    <citation>Fargion S, Porzio M, Fracanzani AL. Nonalcoholic fatty liver disease and vascular disease: state-of-the-art. World J Gastroenterol. 2014 Oct 7;20(37):13306-24. doi: 10.3748/wjg.v20.i37.13306. Review.</citation>
    <PMID>25309067</PMID>
  </reference>
  <reference>
    <citation>Krasnoff JB, Painter PL, Wallace JP, Bass NM, Merriman RB. Health-related fitness and physical activity in patients with nonalcoholic fatty liver disease. Hepatology. 2008 Apr;47(4):1158-66. doi: 10.1002/hep.22137.</citation>
    <PMID>18266250</PMID>
  </reference>
  <reference>
    <citation>Noakes TD. Maximal oxygen uptake: &quot;classical&quot; versus &quot;contemporary&quot; viewpoints: a rebuttal. Med Sci Sports Exerc. 1998 Sep;30(9):1381-98.</citation>
    <PMID>9741607</PMID>
  </reference>
  <reference>
    <citation>Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012 Jun;55(6):2005-23. doi: 10.1002/hep.25762.</citation>
    <PMID>22488764</PMID>
  </reference>
  <reference>
    <citation>Sreenivasa Baba C, Alexander G, Kalyani B, Pandey R, Rastogi S, Pandey A, Choudhuri G. Effect of exercise and dietary modification on serum aminotransferase levels in patients with nonalcoholic steatohepatitis. J Gastroenterol Hepatol. 2006 Jan;21(1 Pt 1):191-8.</citation>
    <PMID>16706832</PMID>
  </reference>
  <reference>
    <citation>Fealy CE, Haus JM, Solomon TP, Pagadala M, Flask CA, McCullough AJ, Kirwan JP. Short-term exercise reduces markers of hepatocyte apoptosis in nonalcoholic fatty liver disease. J Appl Physiol (1985). 2012 Jul;113(1):1-6. doi: 10.1152/japplphysiol.00127.2012. Epub 2012 May 10.</citation>
    <PMID>22582214</PMID>
  </reference>
  <reference>
    <citation>Bae JC, Suh S, Park SE, Rhee EJ, Park CY, Oh KW, Park SW, Kim SW, Hur KY, Kim JH, Lee MS, Lee MK, Kim KW, Lee WY. Regular exercise is associated with a reduction in the risk of NAFLD and decreased liver enzymes in individuals with NAFLD independent of obesity in Korean adults. PLoS One. 2012;7(10):e46819. doi: 10.1371/journal.pone.0046819. Epub 2012 Oct 22.</citation>
    <PMID>23110056</PMID>
  </reference>
  <reference>
    <citation>Kistler KD, Brunt EM, Clark JM, Diehl AM, Sallis JF, Schwimmer JB; NASH CRN Research Group. Physical activity recommendations, exercise intensity, and histological severity of nonalcoholic fatty liver disease. Am J Gastroenterol. 2011 Mar;106(3):460-8; quiz 469. doi: 10.1038/ajg.2010.488. Epub 2011 Jan 4.</citation>
    <PMID>21206486</PMID>
  </reference>
  <reference>
    <citation>Swain MG. Fatigue in liver disease: pathophysiology and clinical management. Can J Gastroenterol. 2006 Mar;20(3):181-8. Review.</citation>
    <PMID>16550262</PMID>
  </reference>
  <reference>
    <citation>Brun P, Castagliuolo I, Di Leo V, Buda A, Pinzani M, Palù G, Martines D. Increased intestinal permeability in obese mice: new evidence in the pathogenesis of nonalcoholic steatohepatitis. Am J Physiol Gastrointest Liver Physiol. 2007 Feb;292(2):G518-25. Epub 2006 Oct 5.</citation>
    <PMID>17023554</PMID>
  </reference>
  <reference>
    <citation>Wigg AJ, Roberts-Thomson IC, Dymock RB, McCarthy PJ, Grose RH, Cummins AG. The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis. Gut. 2001 Feb;48(2):206-11.</citation>
    <PMID>11156641</PMID>
  </reference>
  <reference>
    <citation>Miura K, Ohnishi H. Role of gut microbiota and Toll-like receptors in nonalcoholic fatty liver disease. World J Gastroenterol. 2014 Jun 21;20(23):7381-91. doi: 10.3748/wjg.v20.i23.7381. Review.</citation>
    <PMID>24966608</PMID>
  </reference>
  <reference>
    <citation>Zhu L, Baker SS, Gill C, Liu W, Alkhouri R, Baker RD, Gill SR. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH. Hepatology. 2013 Feb;57(2):601-9. doi: 10.1002/hep.26093. Epub 2013 Jan 8.</citation>
    <PMID>23055155</PMID>
  </reference>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 17, 2015</study_first_submitted>
  <study_first_submitted_qc>August 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 18, 2015</study_first_posted>
  <last_update_submitted>January 10, 2017</last_update_submitted>
  <last_update_submitted_qc>January 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Johannes Gutenberg University Mainz</investigator_affiliation>
    <investigator_full_name>Priv.-Doz. Dr. J. Schattenberg</investigator_full_name>
    <investigator_title>Prov.-Doz. Dr. med.</investigator_title>
  </responsible_party>
  <keyword>NASH</keyword>
  <keyword>fatty Liver</keyword>
  <keyword>VO2 max</keyword>
  <keyword>M30 antigen</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Publication in scientific journals and conferences</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

